Your browser is no longer supported. Please, upgrade your browser.
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.37 Insider Own0.40% Shs Outstand181.77M Perf Week-2.91%
Market Cap14.11B Forward P/E80.58 EPS next Y0.95 Insider Trans-19.25% Shs Float180.42M Perf Month-0.88%
Income-67.30M PEG- EPS next Q-0.11 Inst Own- Short Float6.36% Perf Quarter-11.47%
Sales1.84B P/S7.65 EPS this Y117.90% Inst Trans-0.00% Short Ratio10.32 Perf Half Y1.79%
Book/sh22.90 P/B3.34 EPS next Y275.90% ROA13.80% Target Price108.56 Perf Year-19.76%
Cash/sh5.89 P/C12.98 EPS next 5Y32.16% ROE20.40% 52W Range71.35 - 131.95 Perf YTD-12.89%
Dividend- P/FCF122.92 EPS past 5Y15.10% ROI0.20% 52W High-42.31% Beta0.59
Dividend %- Quick Ratio3.70 Sales past 5Y15.90% Gross Margin71.10% 52W Low6.69% ATR1.85
Employees3059 Current Ratio5.30 Sales Q/Q-3.20% Oper. Margin-6.30% RSI (14)39.74 Volatility2.54% 2.33%
OptionableYes Debt/Eq0.00 EPS Q/Q-78.30% Profit Margin43.10% Rel Volume0.43 Prev Close76.39
ShortableYes LT Debt/Eq0.26 EarningsApr 29 AMC Payout0.00% Avg Volume1.11M Price76.12
Recom2.00 SMA20-3.52% SMA50-2.22% SMA200-8.39% Volume443,041 Change-0.35%
Apr-26-21Resumed Credit Suisse Outperform $102
Mar-04-21Resumed Guggenheim Buy
Mar-01-21Upgrade Evercore ISI In-line → Outperform $90 → $100
Aug-20-20Downgrade William Blair Outperform → Mkt Perform
Aug-20-20Downgrade Citigroup Buy → Neutral $148 → $86
Aug-19-20Downgrade Stifel Buy → Hold $127 → $100
Aug-19-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-19-20Downgrade Evercore ISI Outperform → In-line
Jul-08-20Downgrade Morgan Stanley Overweight → Equal-Weight $125
Jul-06-20Reiterated Citigroup Buy $105 → $148
Jan-28-20Initiated BMO Capital Markets Market Perform
Jan-27-20Initiated BMO Capital Markets Market Perform
Jan-24-20Upgrade RBC Capital Mkts Sector Perform → Outperform $111 → $113
Nov-27-19Upgrade Barclays Equal Weight → Overweight $86 → $98
Nov-12-19Initiated SunTrust Buy $110
Oct-17-19Resumed BofA/Merrill Buy $90
May-23-19Resumed Citigroup Buy
Apr-09-19Resumed Raymond James Outperform
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18Initiated Wolfe Research Outperform
May-04-21 04:03PM  
May-03-21 08:30AM  
04:38AM  
Apr-30-21 09:58AM  
08:49AM  
Apr-29-21 11:31PM  
05:25PM  
04:03PM  
02:30PM  
Apr-28-21 08:31AM  
Apr-22-21 12:33PM  
Apr-15-21 08:31AM  
Apr-13-21 08:30AM  
Mar-30-21 01:23PM  
Mar-27-21 11:31AM  
Mar-23-21 01:53PM  
Mar-21-21 10:02PM  
Mar-20-21 11:15AM  
Mar-19-21 10:50PM  
Mar-12-21 11:29AM  
Mar-09-21 09:05AM  
Mar-08-21 12:05PM  
08:31AM  
Mar-03-21 08:31AM  
Feb-26-21 10:50PM  
12:02PM  
09:16AM  
Feb-25-21 02:30PM  
Feb-24-21 10:09AM  
08:30AM  
Feb-18-21 04:01PM  
Feb-11-21 11:40AM  
Feb-06-21 01:52AM  
Jan-28-21 09:00AM  
Jan-26-21 11:40AM  
08:30AM  
Jan-22-21 07:55AM  
Jan-15-21 10:50PM  
Jan-12-21 09:24AM  
Jan-11-21 10:58AM  
10:14AM  
08:37AM  
08:11AM  
Jan-10-21 06:44PM  
Jan-07-21 11:40AM  
Jan-05-21 08:30AM  
Jan-04-21 08:42AM  
Dec-31-20 09:24AM  
Dec-21-20 08:29AM  
Dec-18-20 12:14PM  
Dec-17-20 04:21PM  
09:42AM  
Dec-14-20 01:38PM  
Dec-09-20 04:02PM  
Dec-05-20 11:32AM  
Dec-01-20 08:30AM  
Nov-24-20 03:35PM  
03:00PM  
11:39AM  
10:15AM  
10:00AM  
09:53AM  
09:13AM  
06:20AM  
Nov-23-20 10:50PM  
05:40PM  
04:10PM  
01:27PM  
12:00PM  
12:00PM  
11:00AM  
11:00AM  
10:15AM  
09:39AM  
06:32AM  
Nov-22-20 10:50PM  
01:00PM  
Nov-21-20 07:00AM  
Nov-20-20 10:50PM  
07:50PM  
07:09PM  
01:00PM  
01:00PM  
11:30AM  
11:20AM  
11:00AM  
09:33AM  
08:00AM  
Nov-19-20 06:09PM  
04:40PM  
04:37PM  
01:57PM  
12:30PM  
12:15PM  
11:08AM  
11:00AM  
10:30AM  
09:49AM  
06:20AM  
Nov-18-20 11:18PM  
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerMay 07Option Exercise26.4925,000662,250328,839May 10 09:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 07Sale78.1225,0001,953,121303,839May 10 09:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 06Option Exercise26.4925,000662,250328,839May 10 09:07 PM
MEIER RICHARD ADirectorMay 06Option Exercise26.4915,000397,35099,340May 07 07:48 PM
MEIER RICHARD ADirectorMay 06Sale78.385,068397,24594,272May 07 07:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 06Sale78.2925,0001,957,199303,839May 10 09:07 PM
Davis George EricEVP, General CounselMay 03Sale78.304,673365,89664,108May 04 08:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 30Option Exercise37.461,00037,460303,498May 03 08:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Option Exercise26.4910,000264,900312,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 23Sale79.3410,000793,400302,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 22Option Exercise26.4910,000264,900312,498Apr 26 08:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 22Sale78.9110,000789,100302,498Apr 26 08:44 PM
Davis George EricEVP, General CounselApr 19Option Exercise26.492,70971,76171,149Apr 20 09:53 PM
Davis George EricEVP, General CounselApr 19Sale79.582,709215,58268,440Apr 20 09:53 PM
LAWLIS V BRYANDirectorApr 15Option Exercise26.497,500198,67526,350Apr 19 04:09 PM
LAWLIS V BRYANDirectorApr 15Sale76.907,500576,75018,850Apr 19 04:09 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerApr 08Sale78.811,537121,13158,250Apr 09 05:57 PM
Mueller BrianEVP, Chief Financial OfficerApr 01Sale76.305,692434,30031,016Apr 02 07:35 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 24Sale76.301,18190,11061,439Mar 26 05:45 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 18Sale77.991,308102,01164,133Mar 19 09:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Option Exercise26.497,000185,430302,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Sale77.107,000539,700295,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Option Exercise26.497,000185,430302,652Mar 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Sale77.687,000543,760295,652Mar 15 08:26 PM
GREY MICHAEL GDirectorMar 05Option Exercise26.495,000132,45047,840Mar 09 05:59 PM
GREY MICHAEL GDirectorMar 05Sale76.285,000381,40042,840Mar 09 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 19Option Exercise26.497,000185,430302,552Feb 22 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 19Sale83.587,000585,060295,552Feb 22 08:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 18Option Exercise26.497,000185,430302,552Feb 19 09:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 18Sale85.087,000595,560295,552Feb 19 09:22 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 17Option Exercise26.498,000211,920303,552Feb 18 09:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 17Sale84.548,000676,320295,552Feb 18 09:45 PM
LAWLIS V BRYANDirectorFeb 16Option Exercise26.497,500198,67526,350Feb 18 06:43 PM
LAWLIS V BRYANDirectorFeb 16Sale87.417,500655,57518,850Feb 18 06:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 29Option Exercise26.498,334220,768303,886Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 29Sale82.678,334688,972295,552Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 28Option Exercise26.498,333220,741303,885Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 28Sale82.918,333690,889295,552Feb 01 07:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 27Option Exercise26.498,333220,741303,885Jan 28 07:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 27Sale85.498,333712,388295,552Jan 28 07:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 29Sale88.181,500132,270295,552Dec 30 08:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale88.771,500133,155297,052Dec 30 08:02 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerOct 14Sale79.912,121169,48961,281Oct 15 07:17 PM
HERON ELAINE JDirectorOct 07Option Exercise26.4915,000397,35066,968Oct 08 08:35 PM
PYOTT DAVID E IDirectorAug 31Buy78.2612,8001,001,71530,740Sep 01 09:44 PM
GREY MICHAEL GDirectorAug 03Option Exercise26.492,50066,22545,340Aug 05 06:56 PM
GREY MICHAEL GDirectorAug 03Sale120.352,500300,87542,840Aug 05 06:56 PM
FUCHS HENRY JPresident, Worldwide R&DJul 20Option Exercise65.97126,3898,337,656229,384Jul 22 05:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 20Sale130.00126,38916,430,570102,995Jul 22 05:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 13Option Exercise65.9723,0111,518,094126,006Jul 15 09:32 PM
FUCHS HENRY JPresident, Worldwide R&DJul 13Sale130.0023,0112,991,430102,995Jul 15 09:32 PM
Dere Willard HDirectorJun 26Sale123.614,430547,59213,290Jun 30 02:11 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 19Option Exercise63.1015,000946,50078,402Jun 23 07:24 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerJun 19Sale124.0015,0001,860,00063,402Jun 23 07:24 PM
LAWLIS V BRYANDirectorJun 05Sale107.464,430476,04818,850Jun 09 06:04 PM